Monitoring urinary orosomucoid in patients undergoing cardiac surgery: A promising novel inflammatory marker

Kabos, Peter; Szirmay, Balázs; Kőszegi, Tamás; Ludány, Andrea; Kovaćs, Gábor L.; Miseta, Attila; Mühl, Diána; Németh, Balázs; Kiss, István; Németh, Ádám; Szabados, S.; Ajtay, Zénó

doi:10.1016/j.clinbiochem.2017.07.010

Cited by 7 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Elevated u‐ORM excretion is supposed to be in association with the activation of the immune system. The several‐fold elevation found in active CD might be in accordance with the former observations related to other inflammatory disorders . This assumption is confirmed by the significant correlations of u‐ORM with conventional inflammatory parameters.…”

Section: Discussionsupporting

confidence: 88%

“…The several-fold elevation found in active CD might be in accordance with the former observations related to other inflammatory disorders. [12][13][14]16,28 This assumption is confirmed by the significant correlations of u-ORM with conventional inflammatory parameters.…”

Section: T a B L E 1 Montreal Classification Of Patientsmentioning

confidence: 66%

“…ORM is normally excreted into the urine in low amounts, and recent studies suggested that urinary orosomucoid (u‐ORM) vs se‐ORM might provide more valuable information on the course of inflammatory disorders and is a non‐invasive tool. Elevated u‐ORM levels were reported in acute and chronic diseases related to inflammatory activation such as sepsis, diabetes, systemic lupus erythematosus, rheumatoid arthritis and even following cardiac surgery . Previously, we identified increased ORM levels in urine samples of CD patients as well …”

Section: Introductionmentioning

confidence: 83%

“…Elevated u-ORM levels were reported in acute and chronic diseases related to inflammatory activation such as sepsis, diabetes, systemic lupus erythematosus, rheumatoid arthritis and even following cardiac surgery. [12][13][14][15][16] Previously, we identified increased ORM levels in urine samples of CD patients as well. 15,17 In the present work, we studied u-ORM excretion in adult and paediatric CD patients to assess u-ORM as a possible objective activity marker of CD.…”

Section: Introductionmentioning

confidence: 93%

See 3 more Smart Citations

Elevated urinary orosomucoid excretion as a novel biomarker in Crohn’s disease

Szirmay

Tárnok

Patrícia

et al. 2018

Eur J Clin Investigation

Self Cite

View full text Add to dashboard Cite

Background Laboratory markers are essential tools in the follow‐up of patients with Crohn's disease (CD). Our aim was to investigate urinary concentrations of orosomucoid in relation to the inflammatory activity of CD and to compare it with clinical indices and conventional laboratory parameters. Materials and methods Blood and urine samples of 86 patients (55 adults and 31 children) with CD and 68 healthy individuals (38 adults and 30 children) as controls were analysed. Patients were categorized according to their clinical scores (Harvey‐Bradshaw Index [HBI] or Pediatric Crohn's Disease Activity Index [PCDAI]). Urinary orosomucoid (u‐ORM) was determined by automated immune turbidimetric assay, and values were referred to urinary creatinine (u‐ORM/u‐CREAT, mg/mmol). Results U‐ORM/u‐CREAT values were seven times higher in children with active CD (0.50 vs 0.07 mg/mmol, P < 0.001) and two times higher in adults (0.32 vs 0.14 mg/mmol, P = 0.01) compared with patients with inactive disease. U‐ORM/u‐CREAT showed good correlation with conventional inflammatory markers (hs‐CRP, serum ORM; P < 0.01) and activity indices (HBI, P = 0.018; PCDAI, P < 0.001). U‐ORM/u‐CREAT had similar discriminative performance to hs‐CRP and serum ORM in the differentiation of active from inactive paediatric CD patients. Conclusions Our findings suggest that u‐ORM/u‐CREAT might serve as a valuable additional marker in the follow‐up of CD patients, especially in children for whom the non‐invasive sampling is a further advantage.

show abstract

Section: Discussionsupporting

confidence: 88%

Section: T a B L E 1 Montreal Classification Of Patientsmentioning

confidence: 66%

Section: Introductionmentioning

confidence: 83%

Section: Introductionmentioning

confidence: 93%

See 2 more Smart Citations

Elevated urinary orosomucoid excretion as a novel biomarker in Crohn’s disease

Szirmay

Tárnok

Patrícia

et al. 2018

Eur J Clin Investigation

Self Cite

View full text Add to dashboard Cite

show abstract

“…It appears that se-ORM is a non-specific and non-sensitive marker of inflammation, thus its clinical value can be questioned. Although recent studies have demonstrated urinary orosomucoid (u-ORM) as a more sensitive, non- invasive biomarker of inflammatory activation than se-ORM, the clinical utility of u-ORM is yet to be explored 17 . Normally urinary excretion of ORM is low and u-ORM concentrations account for only a few mg/L (0.01-0.3 mg/mmol if referred to urinary creatinine), however, increased u-ORM levels have been described in certain acute and chronic diseases 18 - 21 .…”

Section: Introductionmentioning

confidence: 99%

Urinary Orosomucoid A Potential Marker Of Inflammation In Psoriasis

et al. 2018

Self Cite

View full text Add to dashboard Cite

Background: Psoriasis is one of the most common chronic, life-long dermatologic diseases, which has considerable negative effects on quality of life. Psoriasis is considered as a systemic inflammatory disease, thus acute phase proteins such as C-reactive protein (CRP) and orosomucoid (ORM) have been shown to play a role in its pathophysiology. This study was aimed to compare CRP, serum ORM (se-ORM) and urinary ORM (u-ORM) levels of psoriatic patients to healthy individuals.Methods: 87 psoriatic patients and 41 healthy individuals were enrolled. Simultaneously obtained venous blood and spot urine samples were analysed. High sensitivity CRP and se-ORM levels were determined by routine procedures on automated analyzers. Urinary ORM was measured by a novel automated turbidimetric assay. U-ORM was referred to urinary creatinine (u-ORM/u-CREAT, mg/mmol).Results: Significantly higher hsCRP (p<0.001) and u-ORM/u-CREAT (p=0.001) levels were found among psoriatic patients compared to controls. No significant differences were found between the groups regarding se-ORM levels. HsCRP, se-ORM and u-ORM/u-CREAT levels were significantly higher in patients with severe psoriasis than in mild and moderate cases (p<0.05).Conclusion: As a highly sensitive, easily available biomarker u-ORM shows itself capable of becoming a new inflammatory marker in psoriasis providing clinically useful information on disease severity.

show abstract